CA3037157A1 - Metabolite biomarkers for diseases associated with the contact activation system - Google Patents

Metabolite biomarkers for diseases associated with the contact activation system Download PDF

Info

Publication number
CA3037157A1
CA3037157A1 CA3037157A CA3037157A CA3037157A1 CA 3037157 A1 CA3037157 A1 CA 3037157A1 CA 3037157 A CA3037157 A CA 3037157A CA 3037157 A CA3037157 A CA 3037157A CA 3037157 A1 CA3037157 A1 CA 3037157A1
Authority
CA
Canada
Prior art keywords
metabolite
subject
disease
biomarker
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3037157A
Other languages
English (en)
French (fr)
Inventor
Daniel J. Sexton
Malini VISWANATHAN
Ryan Faucette
Tripti GAUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA3037157A1 publication Critical patent/CA3037157A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3037157A 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system Pending CA3037157A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US62/395,770 2016-09-16
US201762518367P 2017-06-12 2017-06-12
US62/518,367 2017-06-12
PCT/US2017/051755 WO2018053247A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Publications (1)

Publication Number Publication Date
CA3037157A1 true CA3037157A1 (en) 2018-03-22

Family

ID=59974882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3037157A Pending CA3037157A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Country Status (12)

Country Link
US (3) US11340237B2 (https=)
EP (1) EP3513197A1 (https=)
JP (4) JP7225090B2 (https=)
KR (3) KR102464380B1 (https=)
CN (2) CN117169508A (https=)
AU (2) AU2017325986B2 (https=)
CA (1) CA3037157A1 (https=)
CO (1) CO2019002607A2 (https=)
IL (2) IL265199B2 (https=)
MX (2) MX2019002918A (https=)
NZ (1) NZ792393A (https=)
WO (1) WO2018053247A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CA3144694A1 (en) 2019-07-25 2021-01-28 Jose A. Horcajadas Identification of viable human embryos
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230174674A1 (en) * 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1711828A2 (en) 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
CA2625744A1 (en) 2005-10-11 2007-04-19 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
WO2008016883A2 (en) * 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008019052A2 (en) 2006-08-03 2008-02-14 Numira Biosciences, Inc. Methods and compositions for identifying biomarkers
WO2008046511A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Crtac as a biomarker, therapeutic and diagnostic target
WO2008046509A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ltbp2 as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
EP2087359A1 (en) 2006-10-16 2009-08-12 Bayer Schering Pharma AG Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
ES2383235T3 (es) 2006-10-16 2012-06-19 Bayer Pharma Aktiengesellschaft CTGF como biomarcador , diana terapéutica y diagnóstica
FR2914066B1 (fr) * 2007-03-20 2009-05-22 Polyintell Sarl Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant
JP5564491B2 (ja) * 2008-04-29 2014-07-30 サイケメディクス コーポレイション 固相多分析物アッセイ法
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK2466312T3 (da) * 2009-08-12 2020-01-13 Human Metabolome Tech Inc Phosphoethanolamine som biomarkør for depression
WO2011051805A1 (en) 2009-10-27 2011-05-05 Anaxomics Biotech Sl Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome
US9494605B2 (en) * 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
EP2550533A4 (en) 2010-03-23 2014-01-08 Purdue Research Foundation EARLY RECOGNITION OF RECYCLING BREAST CANCER BY METABOLIT PROFILING
US20120040383A1 (en) 2010-08-12 2012-02-16 Wei Jia Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
JP5986440B2 (ja) 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
WO2014159637A1 (en) 2013-03-14 2014-10-02 Shire Human Genetic Therapies, Inc. Methods of treating b2-bradykinin receptor mediated angioedema
US9127024B2 (en) * 2013-03-15 2015-09-08 Intrexon Corporation Boron-containing diacylhydrazines
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
EP3805756A1 (en) 2014-04-08 2021-04-14 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US20170343557A1 (en) 2014-09-22 2017-11-30 Kenneth Kun-Yu WU Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system

Also Published As

Publication number Publication date
NZ792393A (en) 2026-01-30
MX2024004195A (es) 2024-04-23
AU2017325986B2 (en) 2023-12-14
IL314752A (en) 2024-10-01
US20190361036A1 (en) 2019-11-28
EP3513197A1 (en) 2019-07-24
WO2018053247A1 (en) 2018-03-22
JP7451791B2 (ja) 2024-03-18
US20250199014A1 (en) 2025-06-19
JP2023058612A (ja) 2023-04-25
JP2019534446A (ja) 2019-11-28
NZ751481A (en) 2024-02-23
MX2019002918A (es) 2019-07-18
CN109716137A (zh) 2019-05-03
JP2024059990A (ja) 2024-05-01
AU2024200561A1 (en) 2024-02-15
KR20220154245A (ko) 2022-11-21
KR102775437B1 (ko) 2025-03-05
JP2025124816A (ja) 2025-08-26
IL265199A (en) 2019-05-30
US12188948B2 (en) 2025-01-07
US11340237B2 (en) 2022-05-24
CO2019002607A2 (es) 2019-03-29
IL265199B2 (en) 2025-01-01
CN117169508A (zh) 2023-12-05
AU2024200561B2 (en) 2026-01-22
BR112019005167A2 (pt) 2019-07-02
CN109716137B (zh) 2023-07-21
IL265199B1 (en) 2024-09-01
KR20190053914A (ko) 2019-05-20
AU2017325986A1 (en) 2019-04-04
US20220365101A1 (en) 2022-11-17
KR102464380B1 (ko) 2022-11-07
KR20250030022A (ko) 2025-03-05
JP7225090B2 (ja) 2023-02-20
JP7692508B2 (ja) 2025-06-13

Similar Documents

Publication Publication Date Title
US12188948B2 (en) Metabolite biomarkers for diseases associated with the contact activation system
AU2026201253A1 (en) Protein biomarkers for diseases associated with the contact activation system
HK40102782A (zh) 用於与接触活化系统相关的疾病的代谢产物生物标记
AU2026202989A1 (en) Metabolite biomarkers for diseases associated with the contact activation system
WO2024003617A2 (en) Protein biomarkers for lanadelumab treatment
BR112019005167B1 (pt) Método e kit para a análise de uma amostra

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220823

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250613

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250811

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112